Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Sinn

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2014
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancersCarsten Denkert, Gunter von Minckwitz, Jan C Brase, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2021
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trialsSonia L Villegas, Valentina Nekljudova, Nicole Pfarr, et al.
Nature Medicine|February 9, 2016
CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinomaElisa M Noll, Christian Eisen, Albrecht Stenzinger, et al.
British Journal of Cancer|February 16, 2024
AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implicationNanna Monjé, Mihnea P Dragomir, Bruno V Sinn, et al.
The Lancet. Oncology|July 12, 2021
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trialsCarsten Denkert, Fenja Seither, Andreas Schneeweiss, et al.
Cell Reports. Medicine|November 20, 2024
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancerCarsten Denkert, Andreas Schneeweiss, Julia Rey, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 2, 2016
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working groupCarsten Denkert, Stephan Wienert, Audrey Poterie, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2014
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancersCarsten Denkert, Gunter von Minckwitz, Jan C Brase, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2021
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trialsSonia L Villegas, Valentina Nekljudova, Nicole Pfarr, et al.
Nature Medicine|February 9, 2016
CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinomaElisa M Noll, Christian Eisen, Albrecht Stenzinger, et al.
British Journal of Cancer|February 16, 2024
AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implicationNanna Monjé, Mihnea P Dragomir, Bruno V Sinn, et al.
The Lancet. Oncology|July 12, 2021
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trialsCarsten Denkert, Fenja Seither, Andreas Schneeweiss, et al.
Cell Reports. Medicine|November 20, 2024
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancerCarsten Denkert, Andreas Schneeweiss, Julia Rey, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 2, 2016
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working groupCarsten Denkert, Stephan Wienert, Audrey Poterie, et al.
Pageof 6